Anti-TNF drugs proven to prevent perianal fistulas in Crohn’s Disease

Early treatment of pediatric Crohn’s disease with anti-tumor necrosis factor medications can substantially reduce the risk of perianal fistulas, a particularly debilitating complication of Crohn’s disease.

Up and down the ladder: The latest comings and goings

Bob Dagher (Courtesy) Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share

July 21, 2023

Sphere Fluidics announces Cyto-Mine Chroma to accelerate and streamline workflows across expanded applications in biotherapeutic discovery and development

Cyto-Mine Chroma enhances single-cell analysis with advanced multiplexing and assay flexibility, optimizing functional screening workflows for researchers.

October 1, 2024

Merck inks deal with Unnatural Products; CG Oncology’s upsized IPO; Locus gets $24M from BARDA

Plus, news about Outlook Therapeutics and Adicet Bio: Merck and Unnatural Products collaborate: Per the deal, Merck will make an undisclosed upfront payment to the

January 24, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.